Abstract

Research Article

The combination of very-small size proteoliposomes and alum is a safe adjuvant alternative for inducing anti-EGF antibodies: a preclinical study

Mabel Cruz Rodríguez, Gretchen Bergado Báez, Yerandy Hechevarría Luna, Diana Rosa Hernández Fernández, Addys González Palomo, Narjara González Suárez, Carlos Yordan González Castillo, María del Carmen Luzardo Lorenzo, Lisset Chao García and Belinda Sánchez Ramírez*

Published: 19 September, 2022 | Volume 6 - Issue 1 | Pages: 018-030

Immunization with human recombinant EGF chemically bound to the P64k protein of Neisseria meningitides (hrEGF-P64k) and adjuvanted in Montanide ISA 51 VG (Montanide) is an efficient strategy to induce polyclonal antibodies (PAbs) response targeting this self -antigen in cancer patients, which is the basis of the CIMAvax-EGF vaccine. The neutralizing potential of EGF-specific induced PAbs supports promising clinical data obtained to date with this vaccine. Herein, we evaluated a combination of very small-size proteoliposomes (VSSP) and aluminum hydroxide (Alum) as a novel adjuvant to induce specific PAbs with neutralizing and anti-proliferative properties on tumor cells, considering EGF as a model antigen. Toxicity at the injection site was not detected for the vaccine formulation containing VSSP/Alum, and it was immunogenic in BALB/c mice, as evidenced by the induction of high titers of EGF-specific polyclonal antibodies (PAbs). While schedule optimization increased the magnitude of the PAbs response induced by VSSP/Alum, induced PAbs’s avidity and intrinsic neutralizing potential were comparable to the humoral response induced by Montanide. Also, VSSP addition switched IgG subclasses distribution into a Th1-like pattern, as obtained with Montanide and desirable for a cancer vaccine. Finally, equivalent PAbs titers were induced by the vaccine formulations adjuvanted in VSSP/Alum or Montanide in tumor-bearing-mice, and immunosuppressed mice, suggesting the feasibility of the VSSP/Alum combined adjuvant for inducing anti-EGF antibodies in cancer patients at advanced stages of the disease.

Read Full Article HTML DOI: 10.29328/journal.acst.1001029 Cite this Article Read Full Article PDF

Keywords:

VSSP; Alum; Montanide; hrEGF- p64; Cancer vaccine; PAbs response; Toxicity; Neutralizing potential

References

  1. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012 Jul 12;12(8):553-63. doi: 10.1038/nrc3309. PMID: 22785351.
  2. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 Jan;16(1):15-31. doi: 10.1517/14728222.2011.648617. Epub 2012 Jan 12. PMID: 22239438; PMCID: PMC3291787.
  3. Uribe ML, Marrocco I, Yarden Y. EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers (Basel). 2021 Jun 1;13(11):2748. doi: 10.3390/cancers13112748. PMID: 34206026; PMCID: PMC8197917.
  4. Purba ER, Saita EI, Maruyama IN. Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model". Cells. 2017 Jun 2;6(2):13. doi: 10.3390/cells6020013. PMID: 28574446; PMCID: PMC5492017.
  5. Kjær IM, Olsen DA, Brandslund I, Bechmann T, Jakobsen EH, Bogh SB, Madsen JS. Prognostic impact of serum levels of EGFR and EGFR ligands in early-stage breast cancer. Sci Rep. 2020 Oct 6;10(1):16558. doi: 10.1038/s41598-020-72944-1. PMID: 33024132; PMCID: PMC7538553.
  6. Bergado Báez G, Hernández Fernández DR, Mazorra Herrera Z, Sánchez Ramírez B. HER1-based vaccine: Simultaneous activation of humoral and cellular immune response. Semin Oncol. 2018 Jan;45(1-2):75-83. doi: 10.1053/j.seminoncol.2018.05.002. Epub 2018 May 31. PMID: 30318087.
  7. Mancebo Rodríguez A, Bergado Báez G, Acosta Lago E, León Goñi A, Blanco Gámez D, Fuentes Morales D, Hernández Fernández DR, Sánchez Ramírez B, Pérez Barreda A, Casacó Parada Á. Immuno-toxicological evaluation of her1 cancer vaccine in non-human primates: a 6-month subcutaneous study. Immunopharmacol Immunotoxicol. 2021 Jun;43(3):283-290. doi: 10.1080/08923973.2021.1900232. Epub 2021 Mar 16. PMID: 33722157.
  8. Saavedra D, Crombet T. CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. Front Immunol. 2017 Mar 13;8:269. doi: 10.3389/fimmu.2017.00269. PMID: 28348561; PMCID: PMC5346887.
  9. Bowen WS, Svrivastava AK, Batra L, Barsoumian H, Shirwan H. Current challenges for cancer vaccine adjuvant development. Expert Rev Vaccines. 2018 Mar;17(3):207-215. doi: 10.1080/14760584.2018.1434000. Epub 2018 Feb 8. PMID: 29372660; PMCID: PMC6093214.
  10. Ascarateil S, Dupuis L. Surfactants in vaccine adjuvants: description and perspectives. Vaccine. 2006 Apr 12;24 Suppl 2:S2-83-5. doi: 10.1016/j.vaccine.2005.01.134. PMID: 16823939.
  11. Oliver L, Fernández A, Raymond J, López-Requena A, Fernández LE, Mesa C. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for antigen-specific cytotoxic T lymphocyte response stimulation under leukopenic conditions. Vaccine. 2012 Apr 19;30(19):2963-72. doi: 10.1016/j.vaccine.2012.02.054. Epub 2012 Mar 3. PMID: 22391399.
  12. Fernández A, Oliver L, Alvarez R, Hernández A, Raymond J, Fernández LE, Mesa C. Very small size proteoliposomes abrogate cross-presentation of tumor antigens by myeloid-derived suppressor cells and induce their differentiation to dendritic cells. J Immunother Cancer. 2014 Mar 11;2:5. doi: 10.1186/2051-1426-2-5. PMID: 24829762; PMCID: PMC4019907.
  13. Mancebo A, Casacó A, González B, Ledón N, Sorlozabal J, León A, Gómez D, González Y, Bada AM, González C, Arteaga ME, Ramírez H, Fuentes D. Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity. Vaccine. 2012 May 9;30(22):3329-38. doi: 10.1016/j.vaccine.2012.01.092. Epub 2012 Mar 17. PMID: 22433960.
  14. van Doorn E, Liu H, Huckriede A, Hak E. Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review. Hum Vaccin Immunother. 2016;12(1):159-69. doi: 10.1080/21645515.2015.1071455. Epub 2015 Sep 17. PMID: 26378866; PMCID: PMC4962750.
  15. Gouttefangeas C, Rammensee HG. Personalized cancer vaccines: adjuvants are important, too. Cancer Immunol Immunother. 2018 Dec;67(12):1911-1918. doi: 10.1007/s00262-018-2158-4. Epub 2018 Apr 11. PMID: 29644387.
  16. Ramírez BS, Pestana ES, Hidalgo GG, García TH, Rodríguez RP, Ullrich A, Férnandez LE. Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9. doi: 10.1002/ijc.22085. PMID: 16841332.
  17. Routhu NK, Cheedarla N, Bollimpelli VS, Gangadhara S, Edara VV, Lai L, Sahoo A, Shiferaw A, Styles TM, Floyd K, Fischinger S, Atyeo C, Shin SA, Gumber S, Kirejczyk S, Dinnon KH 3rd, Shi PY, Menachery VD, Tomai M, Fox CB, Alter G, Vanderford TH, Gralinski L, Suthar MS, Amara RR. SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. Nat Commun. 2021 Jun 11;12(1):3587. doi: 10.1038/s41467-021-23942-y. PMID: 34117252; PMCID: PMC8196016.
  18. Gong H, Kovar J, Little G, Chen H, Olive DM. In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore. Neoplasia. 2010 Feb;12(2):139-49. doi: 10.1593/neo.91446. PMID: 20126472; PMCID: PMC2814352.
  19. Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernandez LE, Crombet, R.S. Kerbel T, Perez R. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. 2011; 11:373-382. doi14097 .
  20. Popa X, García B, Fuentes KP, Huerta V, Alvarez K, Viada CE, Neninger E, Rodríguez PC, González Z, González A, Crombet T, Mazorra Z. Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule. Oncoimmunology. 2020 May 25;9(1):1762465. doi: 10.1080/2162402X.2020.1762465. PMID: 32923124; PMCID: PMC7458606.
  21. Fuentes D, Cabezas-Cruz A, Mesa C, Carmenate T, Martínez D, Valdés-Zayas A, Montero E, Pérez R. Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice. J Breast Cancer. 2022 Jun;25(3):218-232. doi: 10.4048/jbc.2022.25.e18. Epub 2022 Apr 26. PMID: 35657001; PMCID: PMC9250876.
  22. Reinhardt D, Houliara K, Pekrun A, Lakomek M, Krone B. Impact of conventional chemotherapy on levels of antibodies against vaccine-preventable diseases in children treated for cancer. Scand J Infect Dis. 2003;35(11-12):851-7. doi: 10.1080/00365540310016600. PMID: 14723361.
  23. Wang Y, Meng Q, Qiao H, Jiang H, Sun X. Role of the spleen in cyclophosphamide-induced hematosuppression and extramedullary hematopoiesis in mice. Arch Med Res. 2009 May;40(4):249-55. doi: 10.1016/j.arcmed.2009.04.003. Epub 2009 Jun 4. Erratum in: Arch Med Res. 2010 Jan;41(1):66. PMID: 19608013.
  24. Esparís-Ogando A, Montero JC, Arribas J, Ocaña A, Pandiella A. Targeting the EGF/HER Ligand-Receptor System in Cancer. Curr Pharm Des. 2016;22(39):5887-5898. doi: 10.2174/1381612822666160715132233. PMID: 27426127.
  25. Rodríguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev. 2010 Winter;12(1):17-23. doi: 10.37757/MR2010.V12.N1.4. PMID: 20387330.
  26. HogenEsch H, O'Hagan DT, Fox CB. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines. 2018 Oct 10;3:51. doi: 10.1038/s41541-018-0089-x. PMID: 30323958; PMCID: PMC6180056.
  27. Morera Y, Bequet-Romero M, Ayala M, Lamdán H, Agger EM, Andersen P, Gavilondo JV. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis. 2008;11(4):381-93. doi: 10.1007/s10456-008-9121-5. Epub 2008 Nov 26. PMID: 19034678.
  28. Mesa C, De León J, Rigley K, Fernández LE. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine. 2004 Aug 13;22(23-24):3045-52. doi: 10.1016/j.vaccine.2004.02.010. PMID: 15297054.
  29. Caballero I, Aira LE, Lavastida A, Popa X, Rivero J, González J, Mesa M, González N, Coba K, Lorenzo-Luaces P, Wilkinson B, Santiesteban Y, Santiesteban Y, Troche M, Suarez E, Crombet T, Sánchez B, Casacó A, Macías A, Mazorra Z. Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial. Front Pharmacol. 2017 May 10;8:263. doi: 10.3389/fphar.2017.00263. PMID: 28539888; PMCID: PMC5423955.
  30. Morera-Díaz Y, Gavilondo JV, Bequet-Romero M, Sánchez Ramírez J, Hernández-Bernal F, Selman-Housein KH, Perez L, Ayala-Ávila M. Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside. Semin Oncol. 2018 Jan;45(1-2):68-74. doi: 10.1053/j.seminoncol.2018.03.004. Epub 2018 Mar 23. PMID: 30318086.
  31. Suárez NG, Báez GB, Rodríguez MC, Pérez AG, García LC, Hernández Fernández DR, Pous JR, Ramírez BS. Anti-proliferative and pro-apoptotic effects induced by simultaneous inactivation of HER1 and HER2 through endogenous polyclonal antibodies. Oncotarget. 2017 Aug 3;8(47):82872-82884. doi: 10.18632/oncotarget.19958. PMID: 29137309; PMCID: PMC5669935.
  32. Morera Y, Sánchez J, Bequet-Romero M, Selman-Housein KH, de la Torre A, Hernández-Bernal F, Martín Y, Garabito A, Piñero J, Bermúdez C, de la Torre J, Ayala M, Gavilondo JV. Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine. Vaccine. 2017 Jun 16;35(28):3582-3590. doi: 10.1016/j.vaccine.2017.05.020. Epub 2017 May 20. PMID: 28536029.
  33. Hansen B, Belfast M, Soung G, Song L, Egan PM, Capen R, Hogenesch H, Mancinelli R, Hem SL. Effect of the strength of adsorption of hepatitis B surface antigen to aluminum hydroxide adjuvant on the immune response. Vaccine. 2009 Feb 5;27(6):888-92. doi: 10.1016/j.vaccine.2008.11.078. Epub 2008 Dec 9. PMID: 19071182.
  34. García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, González G, Mazorra Z, Lage A, Crombet T. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res. 2008 Feb 1;14(3):840-6. doi: 10.1158/1078-0432.CCR-07-1050. PMID: 18245547.
  35. Saito T, Okada S, Ohshima K, Yamada E, Sato M, Uehara Y, Shimizu H, Pessin JE, Mori M. Differential activation of epidermal growth factor (EGF) receptor downstream signaling pathways by betacellulin and EGF. Endocrinology. 2004 Sep;145(9):4232-43. doi: 10.1210/en.2004-0401. Epub 2004 Jun 10. PMID: 15192046.
  36. Gonzalez G, Montero E, Leon K, Cohen IR, Lage A. Autoimmunization to epidermal growth factor, a component of the immunological homunculus. Autoimmun Rev. 2002 Feb;1(1-2):89-95. doi: 10.1016/s1568-9972(01)00015-5. PMID: 12849064.
  37. Rodriguez PC, Gonzalez I, Gonzalez A, Avellanet J, Lopez A, Perez R, Lage A, Montero E. Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine. Vaccine. 2008 Aug 26;26(36):4647-54. doi: 10.1016/j.vaccine.2008.07.003. Epub 2008 Jul 18. PMID: 18640164.
  38. Garrido G, Rabasa A, Garrido C, López A, Chao L, García-Lora AM, Garrido F, Fernández LE, Sánchez B. Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms. Oncogene. 2014 Jun 12;33(24):3129-39. doi: 10.1038/onc.2013.288. Epub 2013 Aug 26. PMID: 23975426.
  39. Saavedra D, Neninger E, Rodriguez C, Viada C, Mazorra Z, Lage A, Crombet T. CIMAvax-EGF: Toward long-term survival of advanced NSCLC. Semin Oncol. 2018 Jan;45(1-2):34-40. doi: 10.1053/j.seminoncol.2018.04.009. Epub 2018 May 1. PMID: 30318082.
  40. Wang Q, Greene MI. Mechanisms of resistance to ErbB-targeted cancer therapeutics. J Clin Invest. 2008 Jul;118(7):2389-92. doi: 10.1172/JCI36260. PMID: 18568082; PMCID: PMC2430503.
  41. Xu CW, Lei L, Wang WX, Lin L, Zhu YC, Wang H, Miao LY, Wang LP, Zhuang W, Fang MY, Lv TF, Song Y. Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs. Transl Oncol. 2020 Sep;13(9):100791. doi: 10.1016/j.tranon.2020.100791. Epub 2020 May 31. PMID: 32492620; PMCID: PMC7264750.
  42. Lin L, Bivona TG. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemother Res Pract. 2012;2012:817297. doi: 10.1155/2012/817297. Epub 2012 Aug 29. PMID: 22970367; PMCID: PMC3437267.
  43. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008 Jun 26;27(28):3944-56. doi: 10.1038/onc.2008.19. Epub 2008 Feb 25. PMID: 18297114; PMCID: PMC2903615.
  44. Santaniello A, Napolitano F, Servetto A, De Placido P, Silvestris N, Bianco C, Formisano L, Bianco R. Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. Cancers (Basel). 2019 Sep 24;11(10):1419. doi: 10.3390/cancers11101419. PMID: 31554160; PMCID: PMC6826622

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Figure 1

Figure 4

Figure 1

Figure 5

Figure 1

Figure 6

Figure 1

Figure 7

Figure 1

Figure 8

Figure 1

Figure 9

Figure 1

Figure 10

Similar Articles

  • The combination of very-small size proteoliposomes and alum is a safe adjuvant alternative for inducing anti-EGF antibodies: a preclinical study
    Mabel Cruz Rodríguez, Gretchen Bergado Báez, Yerandy Hechevarría Luna, Diana Rosa Hernández Fernández, Addys González Palomo, Narjara González Suárez, Carlos Yordan González Castillo, María del Carmen Luzardo Lorenzo, Lisset Chao García and Belinda Sánchez Ramírez* Mabel Cruz Rodríguez,Gretchen Bergado Báez,Yerandy Hechevarría Luna,Diana Rosa Hernández Fernández,Addys González Palomo,Narjara González Suárez,Carlos Yordan González Castillo,María del Carmen Luzardo Lorenzo,Lisset Chao García,Belinda Sánchez Ramírez*. The combination of very-small size proteoliposomes and alum is a safe adjuvant alternative for inducing anti-EGF antibodies: a preclinical study. . 2022 doi: 10.29328/journal.acst.1001029; 6: 018-030

Recently Viewed

Read More

Most Viewed

Read More